Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naive Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC

Next Previous
X
Search
Trial Profile

A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naive Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine; Ritonavir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 10 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Dec 2012 New source identified and integrated: European Clinical Trials Database EudraCT2011-006187-47.
    • 20 Oct 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top